Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus
Research output: Contribution to journal › Journal article › Research › peer-review
Linagliptin is a xanthine-based dipeptidyl peptidase (DPP)-4 inhibitor that is now available in numerous countries worldwide for the treatment of type 2 diabetes mellitus (T2DM). The aim of this study was to evaluate further the mechanisms underlying the improvements in glycemic control observed with linagliptin. The effects of linagliptin on DPP-4, pharmacodynamic parameters, and glycemic control versus placebo were assessed in patients with inadequately controlled T2DM.
|Publication status||Published - Nov 2012|